215 related articles for article (PubMed ID: 28594340)
1. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors.
Genç CG; Jilesen AP; Partelli S; Falconi M; Muffatti F; van Kemenade FJ; van Eeden S; Verheij J; van Dieren S; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg; 2018 Jun; 267(6):1148-1154. PubMed ID: 28594340
[TBL] [Abstract][Full Text] [Related]
2. International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors.
Heidsma CM; van Roessel S; van Dieren S; Engelsman AF; Strobel O; Buechler MW; Schimmack S; Perinel J; Adham M; Deshpande V; Kjaer J; Norlen O; Gill AJ; Samra JS; Mittal A; Hoogwater FJH; Primavesi F; Stättner S; Besselink MG; van Eijck CHJ; Nieveen van Dijkum EJM
Neuroendocrinology; 2022; 112(6):571-579. PubMed ID: 34343138
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.
Wei IH; Harmon CM; Arcerito M; Cheng DF; Minter RM; Simeone DM
Ann Surg; 2014 Dec; 260(6):1088-94. PubMed ID: 25389924
[TBL] [Abstract][Full Text] [Related]
4. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
5. Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors.
Jiang Y; Jin JB; Zhan Q; Deng XX; Shen BY
Chin Med J (Engl); 2015 Dec; 128(24):3335-44. PubMed ID: 26668149
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
[TBL] [Abstract][Full Text] [Related]
9. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases.
Dong DH; Zhang XF; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
J Surg Oncol; 2019 Dec; 120(7):1071-1079. PubMed ID: 31571225
[TBL] [Abstract][Full Text] [Related]
10. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
12. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size.
Kishi Y; Shimada K; Nara S; Esaki M; Hiraoka N; Kosuge T
Ann Surg Oncol; 2014 Sep; 21(9):2882-8. PubMed ID: 24740828
[TBL] [Abstract][Full Text] [Related]
13. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
14. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of Non-functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden-Based Prediction Model.
Dong DH; Zhang XF; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM
World J Surg; 2021 Jul; 45(7):2134-2141. PubMed ID: 33768309
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
Sallinen V; Haglund C; Seppänen H
Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
[TBL] [Abstract][Full Text] [Related]
17. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.
Cherenfant J; Stocker SJ; Gage MK; Du H; Thurow TA; Odeleye M; Schimpke SW; Kaul KL; Hall CR; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA; Talamonti MS
Surgery; 2013 Oct; 154(4):785-91; discussion 791-3. PubMed ID: 24074416
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.
Xu SS; Xu HX; Wang WQ; Li S; Li H; Li TJ; Zhang WH; Liu L; Yu XJ
World J Gastroenterol; 2019 Nov; 25(41):6248-6257. PubMed ID: 31749595
[TBL] [Abstract][Full Text] [Related]
20. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors.
Pulvirenti A; Javed AA; Landoni L; Jamieson NB; Chou JF; Miotto M; He J; Gonen M; Pea A; Tang LH; Nessi C; Cingarlini S; D'Angelica MI; Gill AJ; Kingham TP; Scarpa A; Weiss MJ; Balachandran VP; Samra JS; Cameron JL; Jarnagin WR; Salvia R; Wolfgang CL; Allen PJ; Bassiy C
Ann Surg; 2021 Dec; 274(6):1051-1057. PubMed ID: 31567347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
